“Nancy and Denise are not only terrific scientists, they are out there in the trenches working to improve the health of the public,” said Groudine. “That’s the kind of person who gets elected.”
Denise Galloway
Galloway’s research helped to establish HPV’s link to cervical cancer, a leading cause of cancer death for women worldwide, and her studies of virus-like particles laid the groundwork for the HPV vaccine, which has dramatically reduced cervical cancer rates in countries that have embraced its use.
“It is terrific to be recognized by your peers,” said Galloway, who holds the Paul Stephanus Memorial Endowed Chair and is director of the Hutch’s Pathogen-Associated Malignancies Integrated Research Center, an interdisciplinary team that is focused on cancers caused by viruses or bacteria. “I attribute any success I have to working at the Hutch. I’ve been here my whole career, and it is a wonderful environment for science.”
Galloway continues her research on the HPV vaccine, including a study in Kenya to see if a single dose of the vaccine is protective. “If we can show that it is feasible there, it will be a game-changer,” she said. “We need to get this cervical cancer vaccine to where the problem is greatest.” Each year, 53O,000 women worldwide are diagnosed with the disease, and 275,000 die from it. Most cases occur in resource-poor countries.
The Hutch scientist has been an advocate for more effective measures to get young people to be vaccinated, such as those adopted by Australia, where HPV infection rates have fallen by 77 percent, and cervical cancer is on track there to be eliminated within two decades. In the United States, only 49 percent girls have received a single dose of the vaccine.